1. Salles G et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2010; 377: 42-51.
2. Salles G et al. ASH 2017, Abstract #486.
3. Rummel MJ et al. ASH 2017, Abstract #483.
4. Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-10.
5. Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl 5): v83-v90.
6. Dreyling M et al. ASH 2017, Abstract #2777.
7. Dreyling M et al. ASH 2017, Abstract #4053.
8. Hoster E et al. ASH 2017, Abstract #153.
9. Rule S et al. ASH 2017, Abstract #151.
10. Wang M et al. ASH 2017, Abstract #155.
11. Crump M et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130: 1800-8.
12. Maude SL et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439-48.
13. Park JH et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018; 378: 449-59.
14. Schuster SJ et al. ASH 2017, Abstract #577.
15. Schuster SJ et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl. J Med 2017; 377: 2545-54.
16. Neelapu SS et al. ASH 2017, Abstract #578.
17. Neelapu SS et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531-44.
18. Neelapu SS et al. ASH 2017, Abstract #579.
19. Siddiqui T et al. ASH 2017, Abstract #193.
20. Sehn L et al. ASH 2017, Abstract #2821.